Boothbay Fund Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Boothbay Fund Management’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.72M	Hold	280,734	–	–	0.02%	797
2026 Q1	$1.49M	Hold	280,734	–	–	0.02%	757
2025 Q4	$2.33M	Hold	280,734	–	–	0.03%	518
2025 Q3	$1.21M	Buy	+280,734	New	+$1.69M	0.02%	755
2025 Q2	–	Sell	-280,735	Closed	-$1.24M	–	1790
2025 Q1	$1.24M	Buy	280,735 +22,030	+9%	+$142K	0.03%	559
2024 Q4	$1.81M	Buy	+258,705	New	+$2.84M	0.04%	475
2022 Q3	–	Sell	-1,667	Closed	-$32K	–	2627
2022 Q2	$32K	Buy	+1,667	New	+$83.8K	﹤0.01%	2155

Other funds holding VRCA

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Boothbay Fund Management's VRCA Position: Q2 2026 in Review

Boothbay Fund Management held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 280,734 shares worth $1.72M. The position accounts for 0.02% of the portfolio, ranked #797.

Boothbay Fund Management first reported a position in VRCA in Q2 2022 and has held it in 7 quarters since. The position peaked at $2.33M in Q4 2025. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

Boothbay Fund Management held 280,734 shares of Verrica Pharmaceuticals worth $1.72M as of Q2 2026.
Boothbay Fund Management left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
Verrica Pharmaceuticals made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #797 holding.
Boothbay Fund Management first reported a position in Verrica Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
Boothbay Fund Management's Verrica Pharmaceuticals position peaked at $2.33M in Q4 2025.
43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.